dexfadrostat phosphate

Phase 2Small molecule

dexfadrostat phosphate is one of 18 small molecule programs targeting Primary Aldosteronism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary AldosteronismActive, not recruiting

Primary AldosteronismPhase 2

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Primary Aldosteronism

#DrugCompanyPhaseTrials

Kerendia

Bayer

Approved

6 2

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 3

Parlodel

VVeroScience

Approved

1 4

Baxfendy

Afinitor

1 6

Decadron

AAspen Global Incorporated

Phase 2

1 7

CIN-107

AstraZeneca

Phase 2

1 8

Aldactone

Pfizer

Preclinical

4 9

HRS-1780

SShandong Suncadia Medicine Co., Ltd.

Phase 2

1 10

CS-3150

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Aldosteronism1 trial

DP13 - A Phase II Study in Patients With Primary Aldosteronism

Completed·DDamian Pharma AG·Phase 2·NCT04007406·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dexfadrostat phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dexfadrostat phosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dexfadrostat phosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Damian Pharma AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDamian Pharma AG

dexfadrostat phosphate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Aldosteronism1 trial

References

Drug Info

Quick Facts

Related News